Volume 19, Number 3—March 2013
Research
Treatment Outcomes for Extensively Drug-Resistant Tuberculosis and HIV Co-infection
Max R. O’Donnell
, Nesri Padayatchi, Charlotte Kvasnovsky, Lise Werner, Iqbal Master, and C. Robert Horsburgh
, Nesri Padayatchi, Charlotte Kvasnovsky, Lise Werner, Iqbal Master, and C. Robert Horsburgh
Table 1
Demographic characteristics of patients with XDR TB, KwaZulu-Natal Province, South Africa*
| Characteristic | All patients, n = 114 | Female patients, n = 65 | Male patients, n = 49 | p value |
|---|---|---|---|---|
| Sex | ||||
| M | 49 (43.0) | NA | NA | NA |
| F |
65 (57.0) |
NA |
NA |
NA |
| Age, y | ||||
| 18–25 | 16 (14.0) | 16 (24.6) | 0 | <0.0001 |
| 26–35 | 42 (36.8) | 27 (41.5) | 15 (30.6) | <0.0001 |
| 36–50 | 46 (40.4) | 21 (32.3) | 25 (51.0) | NA |
| >50 | 10 (8.8) | 1 (1.5) | 9 (18.4) | NA |
| Median age (IQR) |
35 (30–42) |
31 (26–37) |
39 (35–47) |
NA |
| HIV status | ||||
| Positive | 82 (71.9) | 52 (80.0) | 30 (61.2) | 0.0153 |
| Negative | 25 (21.9) | 8 (12.3) | 17 (34.7) | NA |
| Unknown |
7 (6.1) |
5 (7.7) |
2 (4.1) |
NA |
| CD4 cell count/mm3† | ||||
| Known | 55 (67.1) | 38 (73.1) | 17 (56.7) | 0.1487 |
| Not determined | 27 (32.9) | 14 (26.9) | 13 (43.3) | 0.1426 |
| Median (IQR) |
197 (80–300) |
222 (71–316) |
130 (83–254) |
NA |
| Receiving ART† | ||||
| Yes | 50 (61.0) | 34 (65.4) | 16 (53.3) | 0.3492 |
| No |
32 (39.0) |
18 (34.6) |
14 (46.7) |
NA |
| Severe adverse event‡ | ||||
| Yes | 29 (25.4) | 29 (25.4) | 12 (24.5) | 1.0000 |
| No |
85 (74.6) |
48 (73.9) |
37 (75.5) |
NA |
| Previous TB treatment | ||||
| Yes | 92 (80.7) | 53 (81.5) | 39 (79.6) | 0.7216 |
| No | 15 (13.2) | 9 (13.9) | 6 (12.2) | NA |
| Unknown |
7 (6.1) |
3 (4.6) |
4 (8.2) |
NA |
| Previous MDR TB diagnosis | ||||
| Yes | 69 (60.5) | 41 (63.1) | 28 (57.1) | 0.5649 |
| No |
45 (39.5) |
24 (36.9) |
21 (42.9) |
NA |
| Health care worker | ||||
| Yes | 6 (5.3) | 4 (6.2) | 2 (4.1) | 0.6982 |
| No |
108 (94.7) |
61 (93.9) |
47 (95.9) |
NA |
| Type of TB | ||||
| Pulmonary | 103 (90.4) | 58 (89.2) | 45 (91.8) | NA |
| Extrapulmonary |
11 (9.7) |
7 (10.8) |
4 (8.2) |
NA |
| Culture conversion, mo§ | ||||
| None | 72 (63.2) | 40 (61.5) | 32 (65.3) | 0.2523 |
| <2 | 16 (14.0) | 7 (10.8) | 9 (18.4) | NA |
| >2 | 26 (22.8) | 18 (27.7) | 8 (16.3) | NA |
*Values are no. (%) unless otherwise indicated. XDR TB, extensively drug-resistant tuberculosis; NA, not applicable; IQR, interquartile range; ART, antiretroviral therapy; MDR TB, multidrug-resistant TB.
†Among HIV-positive patients only.
‡Resulted in changes in clinical status or electrolyte abnormalities or required change of TB treatment regimen.
§After initiation of treatment.
Page created: March 21, 2013
Page updated: March 21, 2013
Page reviewed: March 21, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.